Effect of Modified Bazhentang on Nutritional Status and Immune Function of Gastric Cancer Patients with Neoadjuvant Chemotherapy
10.13422/j.cnki.syfjx.20210431
- VernacularTitle:八珍汤加减对胃癌新辅助化疗患者营养状况和免疫功能的影响
- Author:
Lu BAI
1
;
Rui SU
1
;
Xing-miao QUAN
1
;
Jing-jing ZANG
1
;
Dong-qi GAO
1
;
Ling-di WANG
1
;
Qing-shan LI
1
;
Xuan ZHONG
2
Author Information
1. Affiliated Hospital of Chengde Medical University，Chengde 067002，China
2. Tangshan Gongren Hospital，Tangshan 063000，China
- Publication Type:Research Article
- Keywords:
gastric cancer;
Qi and blood deficiency syndrome;
neoadjuvant chemotherapy;
Bazhentang;
nutritional status;
immune function
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2021;27(11):117-122
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To observe the effect of modified Bazhentang on the nutritional status and immune function of patients with Qi and blood deficiency syndrome in neoadjuvant chemotherapy （NAC） for gastric cancer. Method:One hundred and ten patients were randomly divided into observation group and control group with 55 cases each. Both groups accepted FOLFOX6 protocol. Patients in control group took Jianpi Shengxue tablets orally， 3 tablets/time， 3 times/day. Patients in observation group received modified Bazhentang， 1 dose/day. The course of treatment was six weeks in both groups. Before and after treatment， scores were graded according to patient generated-subjective global assessment （PG-SGA）， Qi and blood deficiency syndrome， and the Revised Piper Fatigue Scale （PFS-R）. Levels of serum total protein （TB）， albumin （ALB）， prealbumin （PAB）， CD4+， CD8+， helper T lymphocyte 17 （Th17）， regulatory T cell （Treg）， immunoglobulin G （IgG）， IgM， and IgA were detected before and after therapy. Body mass index （BMI） and fat free mass index （FFMI） were measured before and after treatment. Weight loss was recorded， and the acute or subacute toxicity of anticancer drugs was evaluated. Result:The degree of malnutrition in the observation group was lower than that in the control group （Z=2.401，P<0.01）. The levels of TB， ALB and PAB in the observation group were higher than those in the control group （P<0.01）. The CD4+， Treg and CD4+/CD8+ levels in the observation group were higher than those in the control group （P<0.01）. The CD8+， Th17 and Th17/Treg levels were lower than those in the control group （P<0.01）. Besides， the levels of IgM and IgA in the observation group were higher than those in the control group （P<0.01）. The PG-SGA score and weight loss in the observation group were lower than those in the control group （P<0.01）. The BMI and FFMI data of the observation group were higher than those of the control group （P<0.05）. The scores of PFS-R and Qi-blood deficiency syndrome were lower than those of the control group （P<0.01）. The incidence of nausea and vomiting in the observation group was 45.45% （25/55）， lower than 65.45% （36/55） in the control group （χ2=4.452，P<0.05）. Conclusion:Modified Bazhentang can be used to assist gastric cancer patients with NAC， which can improve nutritional status and immune function， promote immune balance， reduce clinical symptoms and fatigue， and reduce chemotherapy toxicity and side effects， so it is worthy of clinical use.
